- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
This infographic details the process for developing long-acting injectables for PrEP and treatment.
Keywords: HIV, ARV, PrEP, treatment, prevention, testing
While scaling up access to all treatment and prevention options that currently exist is essential, it is not sufficient. There remains a critical need for additional options. In addition to the introduction of oral-TDF based PrEP and the open-lable extension studies of the vaginal dapivirine ring, there are a number of efficacy trials planned or underway. They're tackling virtually every intervention—from next-generation PrEP in the form of F/TAF, a drug that will soon be tested for efficacy as daily oral PrEP, to long-acting injectables, vaccines and antibody-mediated prevention.
Within the continuum of reproductive health care, antenatal care (ANC) provides a platform for important healthcare functions, including health promotion, screening and diagnosis, and disease prevention. It has been established that, by implementing timely and appropriate evidence-based practices, ANC can save lives.
Endorsed, by the UN Secretary-General, this is a comprehensive WHO guideline on routine ANC for pregnant women and adolescent girls. It aims to complement existing WHO guidelines on the management of specific pregnancy-related complications. The guidance aims to capture the complex nature of the issues surrounding ANC health care practices and delivery, and to prioritize person-centred health and well-being, not only the prevention of death and morbidity, in accordance with a human rights-based approach.
Keywords: ANC, women, pregnancy, children, adolescent
Scientific evidence is essential for policies and programmes to advance the vision of UNAIDS of zero HIV infections, zero discrimination and zero AIDS-related deaths. New scientific information is becoming available at a rapid pace, and many of the findings are potentially important to guide future action against AIDS. To ensure this, UNAIDS has access to the latest scientific developments; a UNAIDS Scientific Expert Panel was established to advise UNAIDS on major new scientific discoveries and research evidence as well as research gaps and strategic AIDS research needs. The Scientific Expert Panel comprises more than 40 scientists from around the world with expertise in a wide range of disciplines, including epidemiology, behavioural science, virology, diagnostics, pathogenesis, immunology, treatment, prevention and cure.
Given the higher rates of acquisition seen across so-called key populations—members of highly burdened and underserved groups—it is critical to provide access to the research process such that they can participate and reap more immediate benefit of scientific progress. Greater efforts must be made to include key populations in this crucial process for the HIV prevention response to be truly impactful.
Excerpted from Px Wire.
Greatly expanded access to routine viral load testing will be a game-changer in the global response to AIDS. Routine viral load tests improve treatment quality and individual health outcomes for people living with HIV, contribute to prevention, and potentially reduce resource needs for costly second- and third-line HIV medicines.
The publication presents cascade of HIV testing, care and treatment services, 2014–2015 for Bangladesh, Bhutan, India, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand and Timor Leste.
Whether it’s the rising price of the EpiPen, or new outbreaks of diseases, like Ebola, Zika and yellow fever, the rising costs of health technologies and the lack of new tools to tackle health problems, like antimicrobial resistance, is a problem in rich and poor countries alike.
Keywords: TRIPS, Antimicrobial resistance (AMR), health technology, access
In 2000, when the International AIDS Conference was last held in Durban, South Africa, a basic antiretroviral (ARV) regimen cost over US$10,000 per person per year (PPPY), multilateral programmes funding the fight against HIV, TB, and malaria did not exist, and many donors – such as the US government – had yet to provide a single dollar for antiretroviral treatment in resource-limited countries.
See Regional Progress Hepatitis B Vaccination Coverage, 1990—2015, Regional Progress: Status of the 2017 Hepatitis B Control Milestone of <1% HBsAg Prevalence among 5 year old children